Introduction {#sec1-1}
============

Over the past 40 years, non-operative management has become the most common therapy for oropharyngeal squamous cell carcinomas (OPSCC) due to advances in radiotherapy and the significant functional deficits left by traditional surgical approaches. On the other hand, the introduction of trans-oral robotic surgery (TORS) has led to a resurgence in the role of surgery in the management of patients with OPSCC. The oncologic efficacy of TORS is clear and for selected patients, functional outcomes are outstanding ^[@ref1]^. The goal of any oncological therapy should be to achieve long-term disease-free survival while minimising acute and late toxicities. With modern radiotherapy techniques, severe late toxicity is often minimal ^[@ref2]^. Therefore, the decision to pursue an operative versus non-operative strategy is centred on patient and tumour factors identified on history, physical exam and imaging. One of the goals of a TORS resection is to obtain negative margins on the primary tumour with minimal functional morbidity. This issue is most achieved in early OPSCC, clearly localised in an oropharyngeal subsite. Effectively, TORS was approved by the United States Food and Drug Administration for benign and malignant tumours classified as T1-2 in 2009 ^[@ref3]^. Nevertheless, the use of TORS for select locoregionally advanced patients (cT3 or cN2-3) may improve oncologic control compared to chemoradiation (CRT) alone ^[@ref1]^. NCCN guidelines recognise transoral surgery as a potentially useful tool in the treatment of these selected patients ^[@ref1]^. In addition, TORS may be a valuable method of de-intensification for the locoregionally-advanced patient in at least three ways: decreasing the dose of radiotherapy (RT); obviating the need for chemotherapy and decreasing the radiotherapy target volume.

Herein, we specifically investigate our experience in treating OPSCC patients with TORS.

Materials and methods {#sec1-2}
=====================

The medical charts of consecutive patients who underwent TORS for OPSCC at our Department between January 2008 and December 2017 were evaluated retrospectively. Clinicopathologic features of interest included age at surgery, comorbidity, sex, HPV status, final margin status, pathologic T classification, pathologic N classification, overall American Joint Committee on Cancer (AJCC) stage (7^th^ edition), extracapsular spread (ECS) and primary treatment, including TORS alone, TORS and RT, and TORS and CRT. Tumour HPV status was considered positive if either HPV in situ hybridisation or HPV p16 was positive. Exclusion criteria included distant metastases at presentation, primary treatment other than intent-to-cure, or a history of previously treated head and neck squamous cell carcinoma. The surgical approach has previously been described ^[@ref4][@ref5]^. Of note, narrow band imaging (NBI) was used intraoperatively after 2010 to enhance resection of margins ^[@ref4]^. The edges of surgical excision were set at least 1 cm from the tumour. Negative margins or close margins were stated if more than 5 mm or less than 5 mm of surrounding free tissue was present on microscopic evaluation, respectively. Adjuvant RT was recommended for patients with N2b/N2c/N3 disease, close final margins, and all patients with T3 tumours. Adjuvant CRT was recommended for patients with pathologic ECS and positive margins. Recurrence was classified as the time between surgical treatment and the date at which a patient was diagnosed with a local recurrence, nodal recurrence, or distant metastases. A second primary tumour was defined as occurring \> 5 years after initial treatment or occurring in a unique subsite separate from the original tumour bed. Additionally, a re-evaluation of tumour staging based on the 8^th^ edition of the AJCC cancer staging was performed. Disease-free survival (DFS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), total follow-up and 5-year overall survival (OS) were registered.

Statistical analysis {#sec2-1}
--------------------

To test for differences among groups, Fisher's exact test was used for categorical data, while the Student's t-test was used for continuous data. The role of each possible prognostic factor (univariate analysis) and their independent effect (multivariate analysis) was explored using logistic regression model or Cox-proportional hazard model as appropriate. Survival analysis was performed by the Kaplan-Meier method. Probability values lower than 0.05 were considered statistically significant. All analyses were performed with STATA 12.1 software (Stata Corp., College Station, TX, USA).

Results {#sec1-3}
=======

Since 2008, our institution has used TORS mainly to resect hypertrophic bases of tongue (BOT) in case of sleep apnoea disorders and surgically resectable OPSCC. Up to December 2017, 514 TORS procedure were executed. In the same period, a total of 60 OPSCC were treated with TORS alone or in combination with adjuvant RT or CRT based on pathologic cancer staging.

All patients were treated with intent-to-cure. Management strategies included surgery alone in 30% (18/60), TORS-RT in 33.3% (20/60) and TORS-CRT in 36.7% (22/60). Patients undergoing TORS-CRT were more likely to have higher nodal, ECS and overall AJCC stages (p \< 0.001). The primary tumour was classified as cT1(22/60; 36.7%), cT2(23/60; 38.3%), cT3(6/60; 10%) and cTx(9/60; 15%). The primary tumour arose in the BOT in 25 patients (41.7%), tonsils in 28 patients (46.7%), soft palate in 2 (3.3%) and posterior pharyngeal wall in 3 (5%). Unfortunately in 2 cTx, the primary was not found, while the primary was in the palatine tonsil or in the BOT in 3 and 4 cases, respectively (all pT1). Regarding HPV status, 33 (61.1%) were considered HPV-positive.

In all patients, frozen section margins were obtained to check for clear margins. Margins remained clear in 56.7% of patients on final pathology. Of the remaining 26 patients 4 had only positive lateral margin, while 4 had only positive deep margin. Only close lateral margin was found in 5 cases, while 6 had only close deep margin and 3 patients had close both deep and lateral margins. In all, patients with at least one positive margin were 12 (20%) and those with close margins were 14 (23.3%).

The pathological staging according the 7^th^ edition AJCC is shown in [Table I](#table001){ref-type="table"}. The re-evaluation according 8^th^ AJCC is displayed in [Table II](#table002){ref-type="table"} for HPV-/p16-OPSCC and in [Table III](#table003){ref-type="table"} for HPV-related OPSCC. The secondary intention healing was the predominant choice in simple and no-extensive resection's cases (90%; 54/60). One facial artery myo-mucosal (FAMM) and 1 buccinator-based myomucosal (BMM) flaps were used to cover extensive carotid exposure in two patients with a tonsillar cancer (T2). The temporalis myofascial flap (TMF) was adopted to restore a competent velopharyngeal sphincter and a watertight seal between the pharynx and neck in a case of OPSCC involving part of soft palate and the anterior tonsillar pillar (T2). In 3 cases with extensive tumour of BOT involving tonsil and soft palate (T3), the surgical defect was reconstructed with an antero-lateral thigh (ALT) free flap.

Concurrent neck dissection was performed in 26 patients (43.3%). In 15 (25%) cases with high probability of fistula, a staged neck dissection was done after a mean of 27.7 ± 13.4 days (range 8-60). In 7 patients (11.7%), the neck dissection was previously done (-28.1 ± 11.5 days; range -41 to -12) because of the high risk of vascular injury or because the patient was referred to our institution for a primary tumour (unknown cases). The extent of dissection most commonly included levels IIa, IIb, III and IV. The ECS was noted in 24% of neck dissections, and the rate decreased in HPV-related OPSCC (21.4%).

Patients undergoing TORS-RT received a mean dose of 57 ± 5.6 Gy on T (range 50-66 Gy) and a mean of 51.4 ± 15.4 on N (range 0-60). In the TORS-CRT group, a mean dose of 59.7 ± 4.2 Gy of radiation was delivered on T, ranging from 54 to 66, and a mean dose of 59 ± 3.1 on N (range 54-66). Further, TORS-CRT group most commonly received a mean dose of 254.5 ± 46 mg/m^2^ cisplatin (range 180-300).

The mean duration of follow-up for the 60 patients was 30.3 ± 26.9 months. The 5-year OS rate of the total group was 77.6%, in case of HPV-related OPSCC the 5-year OS increased to rate of 88.2%. The 5-year DFS rate was 85.2% (HPV+ group = 93.6%); the 5-year LRFS rate 90.6% (HPV+ group = 96.8%) and 5-year RRFS was 87.4% (HPV+ group = 93.6%).

[Figure 1](#fig001){ref-type="fig"} shows the different survivals by HPV infection.

Data for the univariate and multivariate Cox regression model are shown in [Table IV](#table004){ref-type="table"}. Of note, at univariate analysis positive margins were predictive of regional relapses while HPV-related cancers were related to better OS. However, the statistical significance was lost in multivariate analysis for both factors. On the contrary, at multivariate analysis, tonsillar and BOT cancers were significantly related with a high risk of neck recurrence, but should be considered a bias. In fact, 53 of 60 (88.3%) patients were palatine tonsil or BOT cancers; hence, if only both sites were considered, any statistical significance not correlating the site to any risk of neck recurrence was lost (HR = 6.1, p = 0.27, 95% CI = 0.24-156.06).

Regarding complications, we did not register any major or life-threatening intra-operative complications. Only one patient, who had concurrent neck dissection, experienced post-operative bleeding into the neck. Eight (13.3%) patients had post-operative bleeding from primary tumour resection field; 5 patients from tonsil and 3 from BOT. Oral bleeding had a mean of 6.2 ± 3.7 days. No total local or free flap failure were registered; whilst a partial necrosis of TMF that did not affect the healing and two flap dehiscences (1 FAMM and 1 ALT) that needed a surgical revision were recorded. Only the same ALT patient with flap dehiscence experienced pharyngocutaneous fistula that was treated with both surgical revision and compressive dressings. Tracheostomy was performed routinely in the first series of patients (15 cases until 2012). As our experience increased, tracheostomy was reserved only in difficult intubation cases, cT3 tumours, or cases who needed reconstruction with free flaps or local bulky flaps. The mean duration of tracheostomy use was 7.4 ± 2.6 days, and nasogastric tube 14.3 ± 6.9 days. Only one patient (pT3N2b of BOT invading tonsil and soft palate with ALT reconstruction) experienced a post-operative severe dysphagia, needing a permanent tracheostomy tube and percutaneous endoscopic gastrostomy (PEG) feeding.

Discussion {#sec1-4}
==========

TORS is a fascinating new tool that is useful in the modern management of selected cases of OPSCC. In a systematic review of surgical and nonoperative therapy data for oropharyngeal SCC, Yeh et al. ^[@ref6]^ found that TORS can achieve oncologic outcomes that compare favourably to primary RT, with an improved toxicity profile. In that review, TORS-based therapy OS was reported to range from 81%-100% and DFS from 85.7%-96%. Recently, Moore et al. ^[@ref7]^ reported excellent outcomes with a 1, 3 and 5-year OS rate of 98%, 91% and 86%, DFS of 99%, 96% and 94%, and a local or regional disease-free survival rate of 95%, 93%, and 92%. Furthermore, Mahmoud et al. ^[@ref8]^ demonstrated that 3-year survival was superior in patients undergoing TORS versus non-surgically treated patients (93% vs 83%, p \< 0.001), although patients with HPV-positive disease showed no significant difference in survival by treatment modality (p = 0.116), while the 3 year-survival advantage of TORS over definitive radiotherapy was only evident in the HPV-negative cohort (83% vs 66%, p = 0.2). Our data support these excellent outcomes as the 5-year DFS rate of 85.2% increased to 93.6% in case of HPV-related OPSCC, and a 5-year OS rate of 77.6% (HPV+ group = 88.2%).

An important consideration should be made about surgical margins in TORS for OPSCC. No universal definition of what constitutes an inadequate resection margin exists yet ^[@ref9]^. The guidelines from the American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN) and European Oncology Institute (IEO) all define a close margin as 5 mm or less without any subsite distinction. A published survey of members of the American Head and Neck Society, regarding the definition of margins, revealed that the most common cutoff for a clear margin was greater than 5 mm on microscopic examination ^[@ref10]^. Alicandri-Ciufelli et al. ^[@ref11]^, in their comprehensive review on surgical margins in the head and neck, reported that most studies use a margin distance of 5 mm or greater to define margin clearance, with the exception of glottic cancer in which there is long-standing consensus that resection margins may be as limited as 1 to 2 mm and still be considered adequate. For TORS resection of oropharyngeal tumours, Weinstein et al. ^[@ref12]^ defined a margin of 2 mm or less to be considered close and those greater than 2 mm considered a free margin, which has been adopted at the authors' institution. Obviously, the positive margin rate after TORS for OPSCC widely varies in the literature (2-26%) ^[@ref8][@ref13]^. In our study, we stated that clear margin was \> 5 mm on microscopic evaluation, and thus we obtained 23.3% close margins and 20% positive margins.

This relative high positive margin rate, compared to outcomes at other institutions, might be affected by several factors. Our series also included all patients since the beginning of our robotic experience as well as T3 tumours that are not usually included in most published series. It is well known that the rate of clear margins increases with surgical experience; nevertheless, it is crucial to note that the experience of our pathologists in reporting clear margins increased with the workload over time. In fact, no dedicated head-neck pathologists are present in our institution. Furthermore, our hospital can be considered as a low volume centre. This issue is clearly evident in the literature. Cracchiolo et al. ^[@ref13]^ reported that the incidence of positive margins was higher in lower volume than higher volume hospitals, but improves over time.

On the other hand, other authors have failed to find surgical margin status as a significant prognostic factor in head and neck cancer ^[@ref14]^. Reasons for failing to find a significant impact for margin status include other variables that have a greater impact on prognosis than margins, such as limitations in standard histopathology for assessment of margin status field cancerisation and effect of post-operative RT in negating the adverse impact of positive margins. In addition, technical issues during surgery, such as tearing of the specimen, tissue retraction, or shrinkage cautery effect around tumour margins may lead to close or positive margins on the pathology report, despite complete tumour resection. However, Molony et al. ^[@ref18]^ showed that margin status had no impact on disease specific survival in patients with p16-positive disease. Similarly, Iyer et al. ^[@ref19]^ reported that margin status predicted poorer survival in p16-negative patients, but not among patients who were p16- positive. Moreover, Kaczmar et al. ^[@ref20]^ reported that margins \< 2 mm did not lead to increased recurrence compared with margins \> 2 mm in patients undergoing TORS. Regarding the survival, another study did not demonstrate any significant changes even after excluding TORS-treated patients with HPV-related OPSCC with positive surgical margins from 3-year survival analyses ^[@ref8]^.

Usually tracheostomy is avoided in most (70-100%) cases, regardless of the use of adjuvant therapy ^[@ref21]^, especially in early OPSCC even in case of local flap reconstruction. At many centres, tracheostomy was performed initially at the time of TORS in anticipation of airway oedema during the perioperative period; however, the majority of patients were decannulated within a few days. As the surgeons' experience increased, many of the centres moved away from routine tracheostomy at the time of TORS. In our experience, tracheostomy was routinely performed at the beginnings and then reserved to patients with difficult exposure or those with cT3 that needed regional or free flap reconstruction.

Additionally, TORS is usually associated with low morbidity rates and lower blood loss in comparison with open surgical procedures. These associated characteristics also reflect the shorter average hospital stays (4.2 days). The percutaneous endoscopic gastrostomy (PEG) dependency rate following TORS is 0-9.5% in 1 year and 0% in 2 years ^[@ref22][@ref23]^. Another analysis of 177 patients from a multicentre study reported a long-term tracheostomy rate of 2.3%, and a long-term gastrostomy tube rate of 5%. The average duration of tracheostomy use was 7 days, and nasogastric tube 12.5 days ^[@ref23]^. Our study showed overlapping data. Amongst the TORS studies, the quality of life was investigated in only a few studies. Leonhardt et al. ^[@ref23]^ demonstrated a decline in the eating, diet and speech domains from baseline at 6 months in the postoperative course, but these scores improved to baseline levels for eating and diet by 12 months. Lee et al. ^[@ref24]^ showed improved dysphagia scores when comparing TORS to open surgery with mandibulotomy for patients with T1-T3 tonsil SCC. Dziegielewski et al. ^[@ref25]^ demonstrated a decline in all scores at 3 weeks after surgery, with the lowest scores observed at 3 months in the postoperative course. Speech attitude, aesthetic, social and overall scores eventually returned to baseline, but speech function and aesthetic scores had only partial recovery and remained below baseline scores at 12 months. Two studies included a comparison of quality of life (QOL) outcomes between TORS and RT. More et al. ^[@ref26]^ found that the preoperative and 3 month postoperative MD Anderson Dysphagia Index (MDADI) scores were similar between the two groups. However, by 6 months and at the 12-month postoperative follow-up, patients treated with TORS and adjuvant therapy had significantly better MDADI scores. Chen et al. ^[@ref27]^ compared QOL scales between patients who underwent initial surgical resection with either transoral laser microsurgery or TORS versus definitive CRT. At 1-year, there was no significant difference between the surgical group and the definitive chemoradiation group except for the swallowing score, which was better in the surgical group.

In one of the largest prospective studies of patients undergoing TORS ^[@ref28]^, postoperative dysphagia improved significantly more quickly in the TORS-only group vs. patients who had adjuvant CRT. In summary, the TORS-only group had significantly better scores than the TORS+CRT group in the different QOL questionnaires. Similarly, Sethia et al. ^[@ref29]^ showed that patients who underwent TORS alone had continued improvement in QOL in multiple domains shortly after surgery. These TORS-alone patients reported higher QOL scores in eating at 3 and 6 months postsurgery compared to adjuvant RT or CRT. TORS alone and adjuvant RT reported less social disruption than adjuvant CRT at 3 months, and TORS alone had higher speech scores compared to adjuvant CRT at 3 months and adjuvant RT at 6 months. Adjuvant CRT had lower overall QOL scores compared to adjuvant RT or TORS alone at baseline and 3 months, adjuvant RT at 3 weeks and TORS alone at 6 months. Although many patients in this study received PEG placement, it is important to note that the total number of patients with PEG dependence greatly diminished from 3 to 12 months. Thus, the majority of patients received PEG placement prophylactically as recommended by their radiation oncologist or as a direct result of dysphagia due to adjuvant therapy.

For what concerns surgical complications, fistula formation was noted in the series from the Mayo Clinic in 6% of cases. These patients underwent concurrent neck dissection at the time of TORS. In all four cases, the fistulae responded to treatment with daily packing and antibiotics ^[@ref21][@ref30]^. Postoperative haemorrhage can be a life-threatening event in the case of TORS. The rate of postoperative haemorrhage varied 0% to 9% ^[@ref31]^. Chia et al. ^[@ref36]^ summarised the common complications in a 2013 multi-institutional survey of all TORS-trained surgeons in the United States. An electronic survey was sent to 300 TORS-trained surgeons. Forty-five surgeons responded to the survey and reported a postoperative haemorrhage rate of 3.1% requiring readmission. There were a total of 6 deaths among 2015 procedures (0.3%). Other complications included temporary hypoglossal nerve injury (0.9%), lingual nerve injury (0.6%) and tooth injury (1.4%).

For what concerns reconstructive options, the majority of robotic surgeons favour leaving the oropharyngeal defects to heal by secondary intention following TORS for early OPSCC (cT1-2). However, surgical resection inevitably affects the native function of the oropharynx; therefore our group advocates the use of NBI in order to obtain free margins and reduce over-resections, consequently minimising the risk of functional impairments ^[@ref4]^. Among existing classification schemes for oropharyngeal defects, the reconstructive algorithm developed by de Almeida et al. ^[@ref37]^ seems to be easier to apply in the robotic surgery framework. In our experience, we satisfactorily used FAMM and BMM for class I/II defects ^[@ref38]^. Additionally, in a case of class III defect our group successfully adopted the TMF ([Fig. 2](#fig002){ref-type="fig"}) to restore a competent velopharyngeal sphincter and a watertight seal between the pharynx and neck ^[@ref39]^. In cases of class IV defects, we used the ALT harvested in a particular petal shape that allows one petal to replace the rear side of the palate, one for the front side of the palate and the tonsillar fossa and the third petal to reconstruct the BOT. Flap insetting is the most challenging phase due to severely restricted physical access and visualisation. However, in our experience the accurate shape and measure of the flap allow to thoroughly perform manual inset, although the robot might be used for suturing parts of flap in deeper and narrower spaces.

From an economical point of view, comparing the cost of TORS to the cost of primary radiotherapy is more challenging. In a comparative study, de Almeida et al. ^[@ref40]^ performed an extensive cost-analysis, comparing the cost of TORS versus that of primary RT for the management of early T-classification oropharyngeal cancer. Their study accounted for variations in adjuvant therapy, costs, utilities, complications and recurrence rates. TORS demonstrated a cost savings of \$ 1,366. However, the cost-effectiveness of TORS is unlikely to be realised if used in an unselected fashion. This concept was demonstrated in three recent cost-effectiveness studies comparing TORS and radiotherapy for various populations of OPSCC ^[@ref40]^. The results of each study, although varied in their conclusions, demonstrate significant sensitivity to the frequency of adjuvant therapy. This implies that the use of TORS in unselected patients who are likely to require adjuvant therapy is unlikely to be a cost-effective strategy. Thus, patient selection is the key to the useful application of this modality. Furthermore, the recognition of OPSCC subgroups that would most likely benefit from TORS alone or with adjuvant treatments would be advisable in order to provide a significant treatment opportunity with fewer complications and better quality of life.

Conclusions {#sec1-5}
===========

In selected patients TORS appears to yield similar oncologic outcomes and functional outcomes to traditional techniques and non-operative treatment with a possible benefit on long-term quality of life. Our data demonstrate comparable treatment outcomes to other published larger series. In our practice, TORS is easy and safe, and reconstruction with flaps might increase the surgical indications without compromising oncological and functional outcomes.

The future offers exciting opportunities to combine TORS and radiotherapy in unique ways. However, further research is needed to clarify the indications for and delivery of adjuvant therapy following TORS resections.

Figures and tables {#sec1-6}
==================

![**A)** Local Recurrence-Free Survival; **B)** Regional Recurrence-Free Survival; **C)** Distant Metastasis-Free Survival; **D)** Overall Survival.](aoi-2019-02-75-g001){#fig001}

![Schematic illustration of the oropharyngeal resection suitable for reconstruction with the temporalis muscle flap. **A)** The dotted line shows the surgical resection of the area that includes part of the soft palate and the lateral pharyngeal wall; **B)** The surgical defect with internal carotid artery exposure; **C)** The temporalis muscle flap reconstruction covering the lateral pharyngeal wall and restoring the soft palate.](aoi-2019-02-75-g002){#fig002}

###### 

Clinical TNM classification 7^th^ ed.

  cN (%)                                                     
  -------- ----------- ---------- ------- ---------- ------- -----------
  Tx       0           1 (6.7)    3(60)   4 (36.4)   1(50)   9(15)
  T1       13 (48.2)   5 (33.3)   1(20)   3 (27,3)   0       22 (36.7)
  T2       11 (40.7)   8 (53.3)   1(20)   3 (27.3)   0       23 (38.3)
  T3       3 (11.1)    1 (6.7)    0       1 (9.1)    1(50)   6(10)
  Total    27          15         5       11         2       60

###### 

New pathological TNM classification 8^th^ ed. in HPV-/p16- OPSCC.

  pN (%)                                                          
  -------- ---------- --------- --- --------- -------- ---------- -----------
  T0       0          1(20)     0   0         0        0          1 (4.8)
  T1       2 (33.3)   1(20)     1   1(50)     0        1 (16.7)   6 (29.6)
  T2       3(50)      3 (60%)   0   1 (50%)   1(100)   3(50)      11 (52.4)
  T3       1 (16.7)   0         0   0         0        2 (33.3)   3 (14.3)
  Total    6          5         1   2         1        6          21

###### 

New pathological TNM classification 8^th^ ed. in HPV+/p16+ OPSCC.

  pN (%)                              
  -------- ------- ---------- ------- -----------
  T0       0       1 (6.3)    0       1 (3.6)
  T1       4(40)   8(50)      1(50)   13 (46.4)
  T2       4(40)   6 (37.5)   1(50)   11 (39.3)
  T3       2(20)   1 (6.25)   0       3 (10.7)
  Total    10      16         2       28

  Univariate and multivariate Cox regression model for local relapses                                                                                      
  -------------------------------------------------------------------------------- ---------------- ------------------ ------------ -------- ------------- -------------
  Age                                                                              0.60             0.58               0.1-3.6      0.75     0.84          0.5-11.22
  Tumour site                                                                      0.67             0.53               0.19-2.31    1.38     0.81          0.11-17.92
  pT                                                                               1                1                  0.3-3.25     2.39     0.36          0.37-15.31
  pN                                                                               1.9              0.2                0.71-5       1.6      0.39          0.55-4.62
  Margins                                                                          2                0.16               0.76-5.28    1.96     0.39          0.42-9.19
  HPV                                                                              0.25             0.26               0.02-2.81    0.08     0.23          0.01-4.85
  **Univariate and multivariate Cox regression model for regional relapses**                                                                               
                                                                                   **Univariate**   **Multivariate**                                       
                                                                                   **HR**           **P value**        **95% CI**   **HR**   **P value**   **95% CI**
  Age                                                                              0.7              0.63               0.15-3.08    2.17     0.59          0.13-37.42
  Tumour site                                                                      1.3              0.5                0.6-2.83     6.05     0.03          1.16-31.56
  pT                                                                               1.54             0.39               0.57-4.17    16.2     0.11          0.53-493
  pN                                                                               1.5              0.34               0.67-3.12    1.96     0.28          0.58-6.6
  Margins                                                                          2.7              0.03               1.1-6.7      3        0.27          0.42-21.36
  HPV                                                                              0.36             0.27               0.06-2.19    0.97     0.986         0.05-20.4
  **Univariate and multivariate Cox regression model for disease-free survival**                                                                           
                                                                                   **Univariate**   **Multivariate**                                       
                                                                                   **HR**           **P value**        **95% CI**   **HR**   **P value**   **95% CI**
  Age                                                                              0.92             0.9                0.23-3.66    2.83     0.35          0.32-24.9
  Tumour site                                                                      1.15             0.71               0.54-2.47    2.93     0.13          0.73-11.85
  pT                                                                               1.27             0.6                0.5-3.2      2.7      0.24          0.5-14.47
  pN                                                                               1.65             0.17               0.81-3.32    2.27     0.11          0.83-6.19
  Margins                                                                          2.14             0.06               0.98-4.67    1.59     0.45          0.48-5.27
  HPV                                                                              0.27             0.14               0.05-1.51    0.43     0.51          0.03-5.28
  **Univariate and multivariate Cox regression model for overall survival**                                                                                
                                                                                   **Univariate**   **Multivariate**                                       
                                                                                   **HR**           **P value**        **95% CI**   **HR**   **P value**   **95% CI**
  Age                                                                              0.99             0.98               0.34-2.86    0.28     0.24          0.32-2.38
  Tumour site                                                                      1.39             0.24               0.8-2.42     1.92     0.37          0.47-7.9
  pT                                                                               1                0.99               0.44 2.28    1.57     0.68          0.18-13.88
  pN                                                                               1.11             0.68               0.67-1.85    0.95     0.94          0.26-3.44
  Margins                                                                          1.3              0.33               0.74-2.39    1.94     0.23          0.66-5.71
  HPV                                                                              0.24             0.02               0.07-0.79    0.23     0.16          0.03-1.81
  Neck Dissection                                                                  0.8              0.65               0.3-2.14     0.6      0.56          0.11-3.26
  ECS                                                                              2.23             0.23               0.6-8.36     8.8      0.22          0.27-292.66
  Radiotherapy                                                                     0.7              0.56               0.22-2.25    1.24     0.86          13.6
  Chemotherapy                                                                     0.21             0.13               0.03-1.6     0.03     0.164         0-3.9

HR: hazard ratio; 95% CI: confidence interval; ECS: Extra-capsular spread.
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